Herantis Pharma Plc.

Herantis Pharma Plc. in the PharmaTimes, PharmaTimes Media Ltd, UK. Herantis’ chief executive officer, Antti Vuolanto, commented: “This external validation of Herantis’ science recognises the potential of HER-096 as a promising drug candidate for treatment of PD.” “Disease-modifying treatments that can meaningfully slow the progression of PD are a desperate unmet need for the millions living with this devastating condition,” explained Dr Arthur Roach, director of Parkinson’s Virtual Biotech, Parkinson's UK. #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #PharmaTimes #ParkinsonsUK Read more https://lnkd.in/dSGchcWw

Herantis Pharma Plc., a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease is pleased to announce that The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Parkinson's UK Virtual Biotech will together finance Herantis’ Phase 1b clinical trial of HER-096 in Parkinson’s disease and the on-going biomarker project with research funding of EUR 3.6 million. Read more: https://lnkd.in/dmMKRNKs #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #michaeljfoxorg #parkinsonsUK

We’ve had lots of exciting research announcements over the last few weeks. From a potential blood test which could identify Parkinson’s before symptoms occur, to a trial looking at protecting brain cells in Parkinson's, here is everything you need to know 👇 1. Research co-funded by us shows promise for a blood test that could identify Parkinson’s before movement symptoms occur. Researchers at University College London have developed a test that was 100% accurate in identifying Parkinson’s when comparing blood samples from 99 people with Parkinson’s and 36 people without the condition. The evidence suggests that the test could be used to identify Parkinson’s 7 years before movement symptoms appear and someone receives a diagnosis. Professor David Dexter, our Director of Research, said: “With more work, it may be possible that this blood based test could distinguish between Parkinson’s and other conditions that have some early similarities, such as Multiple Systems Atrophy or Dementia with Lewy Bodies. This is an important next step.” 2. We’re joining forces with The Michael J. Fox Foundation for Parkinson's Research to fund Hernatis on their first trial of an exciting new treatment called HER-096 in people with Parkinson’s. The potential treatment might be able to protect brain cells in Parkinson’s, and has been tested in a study with 60 healthy participants and was shown to be safe with no serious side effects. Arthur Roach, our Virtual Biotech Director, said: “We hope this study will show that HER-096 is safe and that it has the potential to be a life-changing therapy for people with Parkinson’s in the future.” 3. We’re also teaming up with The Michael J. Fox Foundation for Parkinson's Research and Mission Therapeutics to see whether a potential new treatment, MTX325, is safe, gets into the brain and improves energy production in brain cells of people with Parkinson’s. The clinical trial is in the planning stages and we hope there will be an opportunity for a small number of people with Parkinson’s in the UK to take part. If you would like to read more about our latest research updates, please visit 👉 https://prksn.uk/4ck57Ea

Herantis Pharma Plc., a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease is pleased to announce that The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Parkinson's UK Virtual Biotech will together finance Herantis’ Phase 1b clinical trial of HER-096 in Parkinson’s disease and the on-going biomarker project with research funding of EUR 3.6 million. Read more: https://lnkd.in/dmMKRNKs #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #michaeljfoxorg #parkinsonsUK

🔬 We have initiated coverage of Herantis Pharma Plc., a drug development company focusing on neurodegenerative diseases. The first report by our analyst Antti Siltanen is now available in both English and Finnish. Check out the report here: 🇬🇧 https://lnkd.in/dQtPzDKR 🇫🇮 https://lnkd.in/dFbUHwdG #HerantisPharma #DrugDevelopment #Biotech #Research

Herantis Pharma Plc.’ CSO, Henri Huttunen has been interviewed by Open Access Government. Topic for the interview: Symptomatic vs. Disease-modifying treatments in neurological diseases: Where next? Check out the full interview here: https://lnkd.in/dJMnirrd #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #OpenAccessGovernment

Deep dive into the world of biotechnology! This session is happening on 18th September during NLSDays 2024 and will feature company presentations from: 11:00 Abliva AB 11:05 CombiGene 11:10 Dicot Pharma AB 11:15 Herantis Pharma Plc. 11:20 Insilico Medicine 11:25 Neumirna Therapeutics 11:30 AdjuTec Pharma AS 11:35 Lund University 11:40 Scandion Oncology Register here: https://lnkd.in/d5TT8sX

Herantis Pharma Plc., a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease is pleased to announce that their EIC Accelerator project, ReTreatPD, is progressing as planned and Herantis will receive a milestone payment of EUR 750,000. Read more https://lnkd.in/dyNb9mVa #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology

Herantis Pharma’s research article, first published May 22, 2023: Intraputamenally administered CDNF was safe and well tolerated, and possible signs of biological response to the drug were observed in individual patients. 

Herantis Pharma Plc.’s scientific paper, Brain-penetrating neurotrophic factor mimetics: HER-096 as a disease-modifying therapy for Parkinson’s disease published in Neural Regeneration Research. Read more: https://lnkd.in/drjEYhS7 #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #healthtech #drugdevelopment #pharma #Neurology #NeuralRegenerationResearch